CurifyLabs raises €12M to automate personalised medicine
CurifyLabs is bringing software, GMP-ready materials and 3D printing into pharmaceutical compounding to make personalised medicine more scalable.
Personalised medicine is often discussed through diagnostics and drug discovery. CurifyLabs is attacking a different bottleneck: how customised medicines are actually produced.
What happened
Finnish healthtech company CurifyLabs raised a €12M Series A, co-led by Sandwater and HealthCap.
Its platform combines software, GMP-manufactured excipient bases and 3D-printing technology to automate pharmaceutical compounding. The company says its systems are already used by pharmacies across 21 U.S. states and Europe.
Why it matters
Compounding is traditionally manual, labour-intensive and difficult to standardise. That limits how easily pharmacies can produce medicines tailored to specific doses or patient needs.
CurifyLabs is trying to turn a highly specialised workflow into a more repeatable manufacturing system. If it works, pharmacies could expand personalised treatment without relying on the same level of manual preparation.
The value therefore sits at the intersection of healthcare software and physical production.
The bigger picture
Healthcare is becoming more personalised, but the production layer has to catch up. Better diagnostics and more targeted therapies create demand for flexible manufacturing closer to the patient.
CurifyLabs fits that shift by treating compounding as an automation problem rather than only a pharmacy craft.